Trials / Completed
CompletedNCT02691767
Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single arm, pilot study of pazopanib in patient with FGFR2 amplification Refractory solid tumor and/or specific sensitivity to pazopanib by Avatar scan that has progressed following standard therapy or that has not responded to standard therapy or for which there is no standard therapy. To investigate the efficacy and safety of pazopanib in patient with Refractory solid tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pazopanib |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2018-01-16
- Completion
- 2020-02-13
- First posted
- 2016-02-25
- Last updated
- 2022-06-15
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02691767. Inclusion in this directory is not an endorsement.